Foster Graham R.

Podsumowanie dorobku w bazie danych

5
publikacji (2017–2019)
7,512
łączny Impact Factor
200
łącznie punktów MNiSW

Identyfikatory

BPP ID
41225

Publikacje w latach

30

Punkty MNiSW w latach

200,000

Impact Factor w latach

7,5120

Statystyki wg charakteru

Charakter formalnyLiczba prac
3
2
Razem5

Najczęstsi współautorzy

  • (5)
  • (3)
  • (2)
  • (2)
  • (2)
  • (2)
  • (2)
  • (2)
  • (2)
  • (2)
Zobacz pełną sieć powiązań

Wyszukaj publikacje autora

Bez zaznaczonych filtrów wyszukiwanie pokaże wszystkie prace autora. Zaznacz typy, lata lub jednostki, żeby zawęzić wyniki.

Typ publikacji
Lata
Jednostki

Najlepsze prace (punkty MNiSW)

  1. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies. [AUT. KORESP.] GRAHAM R. FOSTER, [AUT.] GREGORY J. DORE, STANLEY WANG, JASON GREBELY, KENNETH E. SHERMAN, AXEL BAUMGARTEN, BRIAN CONWAY, DANIEL JACKSON, TARIK ASSELAH, MICHAEL GSCHWANTLER, KRZYSZTOF TOMASIEWICZ, HUMBERTO AGUILAR, ARMEN ASATRYAN, YIRAN HU, FEDERICO J. MENSA. Drug Alcohol Depend. 2019 vol. 194 s. 487-494, bibliogr. poz. 44. DOI: 10.1016/j.drugalcdep.2018.11.007
  2. Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132

Najlepsze prace (Impact Factor)

  1. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies. [AUT. KORESP.] GRAHAM R. FOSTER, [AUT.] GREGORY J. DORE, STANLEY WANG, JASON GREBELY, KENNETH E. SHERMAN, AXEL BAUMGARTEN, BRIAN CONWAY, DANIEL JACKSON, TARIK ASSELAH, MICHAEL GSCHWANTLER, KRZYSZTOF TOMASIEWICZ, HUMBERTO AGUILAR, ARMEN ASATRYAN, YIRAN HU, FEDERICO J. MENSA. Drug Alcohol Depend. 2019 vol. 194 s. 487-494, bibliogr. poz. 44. DOI: 10.1016/j.drugalcdep.2018.11.007
  2. Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132

Najnowsze artykuły

  1. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies. [AUT. KORESP.] GRAHAM R. FOSTER, [AUT.] GREGORY J. DORE, STANLEY WANG, JASON GREBELY, KENNETH E. SHERMAN, AXEL BAUMGARTEN, BRIAN CONWAY, DANIEL JACKSON, TARIK ASSELAH, MICHAEL GSCHWANTLER, KRZYSZTOF TOMASIEWICZ, HUMBERTO AGUILAR, ARMEN ASATRYAN, YIRAN HU, FEDERICO J. MENSA. Drug Alcohol Depend. 2019 vol. 194 s. 487-494, bibliogr. poz. 44. DOI: 10.1016/j.drugalcdep.2018.11.007
  2. Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132

Ostatnio edytowane

  1. C-BREEZE 2: Efficacy and safety of a two-drug direct-acting antiviral agent (DAA) regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus (HCV) genotype (GT)1, 2, 3, 4, or 6. [AUT.] E. LAWITZ, J. GANE, J.J. FELD, M. BUTI, G. R. FOSTER, E.Z. BURNEVICH, I.M. SECHENOV, H. KATCHMAN, F. LAHSER, B. JACKSON, M. SHAUGHNESSY, S. KLOPFER, W.W. YEH, M. ROBERTSON, G.J. HANNA, E. BARR, H. PLATT, K[RZYSZTOF] TOMASIEWICZ. W: The Liver Meeting 2017 (AASLD). Washington, October 20-24, 2017 [online]. [Abstr.] [b. pag.] 61, [przeglądany 10 kwietnia 2018]. Dostępny w: https://liverlearning.aasld.org/aasld/2017/thelivermeeting/201248/eric.lawitz.c-breeze.2.efficacy.and.safety.of.a.two-drug.direct-acting.html?f=ce_id=1198*ot_id=17909*media=3*speaker=15815.
  2. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 and recent drug use. [AUT.] G. R. FOSTER, J. GREBELY, G.J. DORE, K.E. SHERMAN, S. WANG, N. ALAMI, E.O. DUMAS, Y. HU, F. MENSA, B. CONWAY, D.F. JACKSON, T. ASSELAH, M. GSCHWANTLER, K[RZYSZTOF] TOMASIEWICZ, H.I. AGUILAR. W: The Liver Meeting 2017 (AASLD). Washington, October 20-24, 2017 [online]. [Abstr.] [b. pag.] 1182, [przeglądany 10 kwietnia 2018]. Dostępny w: https://liverlearning.aasld.org/aasld/2017/thelivermeeting/194730/graham.foster.safety.and.efficacy.of.glecaprevir.pibrentasvir.in.patients.with.html?f=media=3*speaker=15319.
  3. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies. [AUT. KORESP.] GRAHAM R. FOSTER, [AUT.] GREGORY J. DORE, STANLEY WANG, JASON GREBELY, KENNETH E. SHERMAN, AXEL BAUMGARTEN, BRIAN CONWAY, DANIEL JACKSON, TARIK ASSELAH, MICHAEL GSCHWANTLER, KRZYSZTOF TOMASIEWICZ, HUMBERTO AGUILAR, ARMEN ASATRYAN, YIRAN HU, FEDERICO J. MENSA. Drug Alcohol Depend. 2019 vol. 194 s. 487-494, bibliogr. poz. 44. DOI: 10.1016/j.drugalcdep.2018.11.007
  4. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 and recent drug use. [AUT.] GRAHAM R. FOSTER, JASON GREBELY, KENNETH E. SHERMAN, STANLEY WANG, GREGORY J. DORE, AXEL BAUMGARTEN, BRIAN CONWAY, DANIEL F. JACKSON, TARIK ASSELAH, MICHAEL GSCHWANTLER, KRZYSZTOF TOMASIEWICZ, HUMBERTO I. AGUILAR, NEGAR NIKI ALAMI, EMILY O. DUMAS, YIRAN HU, FEDERICO J. MENSA. Hepatology 2017 vol. 66 suppl. 1 s. 636A-637A, The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting. Washington, October 20-24, 2017. Abstr.
  5. Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132